natgillin/translations-raw huggingface dataset:
If UPC ratio > 2, or creatinine > 1.5 upper limit of normal (ULN), or albumin < 0.75 lower limit of normal (LLN) or blood urea nitrogen (BUN) > 1.5 ULN, discontinue treatment.
Če je razmerje UPC > 2 ali vsebnost kreatinina > 1, 5- kratnika zgornje meje normalnih vrednost (ULN) ali vsebnost albumina < 0, 75- kratnika spodnje meje normalnih vrednost (LLN) ali vsebnost dušika sečnine v krvi (BUN) > 1, 5- kratnika zgornje meje normalnih vrednost, z zdravljenjem prenehajte.
In case of positive semi-quantitative dipstick results (protein ≥ 30 mg/dL), perform urinalysis to determine urinary protein creatinine (UPC) ratio.
Nadzor sindrom izgube beljakovin V primeru pozitivnega rezultata testiranja s semikvantitativnimi testnimi lističi (beljakovine > 30 mg/ dl), izvedite preiskavo urina za določitev razmerja beljakovin in kreatinina (UPC).
27 Anaemia and / or haemolysis Dogs should be carefully monitored for signs of (haemolytic) anaemia.
Anemija in/ ali hemoliza Pse je treba skrbno spremljati glede znakov (hemolitične) anemije.
Haemolytic anaemia, i.e. haemoglobin < 10 g/dL and haemolysis, i.e. free bilirubin > 1.5 ULN and haptoglobin < 0.1 g/dL, Anaemia due to lack of regeneration, i.e. haemoglobin < 10 g/dL and reticulocytes < 80,000/mm3.
Z zdravljenjem je treba prenehati v primeru: hemolitične anemije, tj. vrednosti hemoglobina < 10 g/ dl, in hemolize, tj. vrednosti prostega bilirubina > 1, 5- kratnika ULN in haptoglobina < 0, 1 g/ dl, anemije zaradi pomanjkljive regeneracije, tj. vrednosti hemoglobina < 10 g/ dl in retikulocitov < 80. 000/ mm3.
Hepatic toxicity (ALT or AST elevation), neutropenia In case of an increase of ALT or AST > 3 ULN, decrease of neutrophil count < 2000/mm3 or any other severe adverse events, treatment should be modified as follows:
27 Hepatotoksičnost (povišana vrednost ALT ali AST), nevtropenija V primeru povečanja vrednosti ALT ali AST > 3 ULN, znižanja števila nevtrofilcev < 2000/ mm3 ali katerega drugega neželenega učinka je treba zdravljenje spremeniti kot sledi:
At the first occurrence, treatment should be interrupted until resolution, then resumed at the same dose level; At the second occurrence of the same event, treatment should be interrupted until resolution; treatment should then be continued with a reduced dose of 9 mg/kg bodyweight/day; At the third occurrence of the same event, treatment should be interrupted until resolution; treatment should then be continued with a dose further reduced to 6 mg/kg/day; Treatment should be discontinued, if severe adverse reactions are still encountered at the 6 mg/kg/day dose.
Če se neželeni učinki pojavljajo tudi pri odmerku 6 mg/ kg/ dan, je treba z zdravljenjem prenehati.
CONTRA-
KONTRAINDIKACI
TREATMENT
PREKINITEV
DOSE REDUCTION
ZMANJŠANJE
TREATMENT
PRENEHANJE
INDICATION
ZDRAVLJENJA
INTERRUPTION
ODMERKA
DISCONTINUATION
ZDRAVLJENJA
MANAGEMENT OF HEPATIC TOXICITY (ALT or AST)
OBVLADOVANJE HEPATOTOKSIČNOSTI (ALT ALI AST)
> 3 ULN
> 3ULN
(2nd/3rd time)
(drugič/ tretjič)
MANAGEMENT OF NEUTROPENIA (Neutrophil counts)
OBVLADOVANJE NEVTROPENIJE (število nevtrofilcev)
Albumin < 1 LLN
OBVLADOVANJE SINDROMA IZGUBLJANJA BELJAKOVIN (albuminemija in/ ali UPC) albumin < 1 LLN
MANAGEMENT OF HAEMOLYTIC AND AREGENERATIVE ANAEMIA (haemoglobin, bilirubin, haptoglobin, reticulocytes) Haemoglobin < 10g/ dL and either
OBVLADOVANJE HEMOLITIČNE IN AREGENERATIVNE ANEMIJE (hemoglobin, bilirubin, haptoglobin, retikulociti) hemoglobin < 10 g/ dl in bodisi
Haemoglobin < 10g/dL
prosti bilirubin > 1, 5 hemoglobin < 10 g/ dl
Not applicable Not applicable
navedba ni smiselna
free bilirubin > 1.5 ULN and haptoglobin < 0.1g/dl or reticulocytes < 80,000/mm3
haptoglobin < 0, 1 g/ dl
28 Dose adjustment
Prilagoditev odmerka
The recommended daily dose of 12.5 mg/kg body weight corresponds to the Maximum Tolerated Dose (MTD) that was derived from repeat dose toxicity studies in healthy Beagle dogs.
Priporočeni dnevni odmerek 12, 5 mg/ kg telesne mase ustreza največjemu tolerančnemu odmerku (MTD - Maximum Tolerated Dose), ki je bil izpeljan iz toksikoloških študij s ponovljenimi odmerki, izvedenih z zdravimi psi pasme Beagle.
In the case of adverse reactions, doses might be reduced to once daily doses of 9 mg/kg bodyweight (range 7.5 – 10.5 mg/kg) or 6 mg/kg bw (range 4.5 – 7.5) according to the tables below.
V primeru neželenih reakcij je odmerke mogoče zmanjšati na enkrat dnevno 9 mg/ kg telesne mase (razpon 7, 5 – 10, 5 mg/ kg) ali 6 mg/ kg telesne mase (razpon 4, 5 – 7, 5) v skladu s spodnjimi tabelami.
9 mg per kg bodyweight
28 9 mg na kg telesne mase
Number of tablets per day Dose mg/kg
Število tablet Odmerek mg/ kg na dan
7.7 8.0 8.2 8.3 8.4 8.5 8.5 8. 6 8.6 8.6 8.7 8.7
7, 7 8, 0 8, 2 8, 3 8, 4 8, 5 8, 5 8, 6 8, 6 8, 6 8, 7 8, 7
> 15.0 > 20.8> 29.2> 37.5> 45.8> 54.2 62.5> 70.8> 79.2
> 15, 0 > 20, 8 > 29, 2 > 37, 5 > 45, 8 > 54, 2 62, 5 > 70, 8 > 79, 2
Meloxivet contains the active substance meloxicam and exists in 2 different strengths (0.5 and 1.5 mg/ ml, respectively).
Zdravilo Meloxivet vsebuje zdravilno učinkovino meloksikam in je na voljo v 2 različnih jakostih (0, 5 in 1, 5 mg/ ml).
Meloxivet is a ‘ generic’: this means that Meloxivet is similar to a ‘ reference veterinary medicine ’ already authorised in the EU (Metacam 1.5 mg/ ml oral suspension).
Zdravilo Meloxivet je „ generično “ zdravilo, to pomeni, da je podobno „ referenčnemu veterinarskemu zdravilu “, ki je že bilo odobreno v EU (zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija).
Studies have been carried out to prove that Meloxivet is ‘ bioequivalent ’ to the reference veterinary medicine: this means that Meloxivet is equivalent to Metacam 1.5 mg/ ml suspension in the way it is absorbed and used by the body.
Študije so pokazale, da je zdravilo Meloxivet „ bioekvivalentno “ referenčnemu veterinarskemu zdravilu, to pomeni, da je zdravilo Meloxivet enako zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija glede načina, kako ga telo absorbira in uporabi.
Meloxivet is used in dogs to relieve inflammation and pain in musculo-skeletal disorders.
Zdravilo Meloxivet se uporablja pri psih za lajšanje vnetja in bolečin pri mišično- kostnih obolenjih.
Meloxivet is given to the dog once a day, with food, at the dose of 0.2 mg/ kg on the first day, then as 0.1 mg/ kg afterwards.
Zdravilo Meloxivet se psu daje enkrat dnevno s hrano v odmerku 0, 2 mg/ kg na prvi dan, zatem pa v odmerku 0, 1 mg/ kg.
A study looked at how Meloxivet was absorbed and its effects in the body, in comparison with Metacam 1.5 mg/ ml oral suspension.
V študiji so preučevali absorbiranje zdravila Meloxivet ter njegove učinke na telo v primerjavi z zdravilom Metacam 1, 5 mg/ ml peroralna suspenzija.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What are the side-effects of Meloxivet?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 47 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšni so neželeni učinki zdravila Meloxivet?
The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Meloxivet has been shown to be bioequivalent to Metacam 1.5 mg/ ml oral suspension.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da se je zdravilo Meloxivet v skladu z zahtevami Evropske unije izkazalo kot bioekvivalentno zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija.
Therefore the CVMP’ s view was that, as for Metacam 1.5 mg/ ml oral suspension, Meloxivet’ s benefits are greater than its risks when treating inflammation or pain in muscles or joints in dogs and they recommended that Meloxivet should be given a marketing authorisation.
Zato je CVMP menil, da so koristi zdravila Meloxivet enako kot pri zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija večje od z njim povezanih tveganj pri zdravljenju vnetja ali bolečine v mišicah ali sklepih pri psih, ter je priporočil odobritev dovoljenja za promet z zdravilom Meloxivet.
The European Commission granted a marketing authorisation valid throughout the European Union, for Meloxivet to Janssen Pharmaceutica N. V. on 14 November 2007 Information on the prescription status of this product may be found on the label of the carton.
Podatki o predpisovanju tega zdravila so navedeni na nalepki na zunanji ovojnini.
Page 2/ 2 ©EMEA 2007
Stran 2/ 2 ©EMEA 2007
Invented Name
Lastniško ime Jakost
EU/ 2/ 07/ 077/ 001 Meloxivet
EU/ 2/ 07/ 077/ 001 Meloxivet
0.5 mg/ ml
0. 5 mg/ ml Peroralna suspenzija.
EU/ 2/ 07/ 077/ 002 Meloxivet
EU/ 2/ 07/ 077/ 002 Meloxivet
30 ml
30ml
EU/ 2/ 07/ 077/ 003 Meloxivet
EU/ 2/ 07/ 077/ 003 Meloxivet
1.5 mg/ ml
1. 5 mg/ ml Peroralna suspenzija.
EU/ 2/ 07/ 077/ 004 Meloxivet
EU/ 2/ 07/ 077/ 004 Meloxivet
EU/ 2/ 07/ 077/ 005 Meloxivet
EU/ 2/ 07/ 077/ 005 Meloxivet
N/ A
Navedba smiselno ni potrebna. ml
Meloxivet 0.5 mg/ ml oral suspension for dogs
Meloxivet 0, 5 mg/ ml, peroralna suspenzija za pse
Composition for 1 ml:
Sestava 1 ml:
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Ne uporabljajte pri psih, ki imajo gastrointestinalne motnje kot sta iritacija in krvavitev, oslabljeno delovanje jeter, srca ali ledvic ter hemoragične motnje.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Izogibajte se uporabi pri psih z dehidracijo, hipovolemijo ali hipotenzijo, saj lahko povzroči povečano renalno toksičnost.
2/ 28 Special precautions to be taken by the person administering the veterinary medicinal product to animals
2/ 28 Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe, preobčutljive na nesteroidna protivnetna zdravila (NSAR), se morajo izogibati stiku z veterinarskim zdravilom.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported.
Občasno so poročali o značilnih neželenih učinkih nesteroidnih protivnetnih zdravil, kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev) in apatija.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3).
Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena (glejte razdelek 4. 3).
Pre- treatment with anti-inflammatory substances may result in additional or increased adverse reactions and accordingly a treatment-free period with such should be observed for at least 24 hours before commencement of treatment.
Predzdravljenje z zdravili s protivnetnim delovanjem lahko povzroči dodatne neželene učinke ali jih okrepi, zato teh zdravil ne smemo dajati najmanj 24 ur pred začetkom zdravljenja.
The treatment-free period, however, should take into account the pharmacokinetic properties of veterinary products used previously.
Poleg tega je treba pri določanju obdobja brez zdravil upoštevati farmakokinetične lastnosti zdravil, ki smo jih dajali predhodno.
Treatment is to be continued once daily by oral administration (24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/ kg body weight.
Zdravljenje nadaljujemo z enim peroralnim, vzdrževalnim odmerkom (v 24 urnih intervalih) 0, 1 mg meloksikama na kilogram telesne mase.
0.1 mg meloxicam/ kg body weight).
Brizga se prilega na stekleničko in ima merilno skalo z oznakami telesne mase v kilogramih, ki ustrezajo vzdrževalnemu odmerku (0, 1 mg meloksikama na kilogram telesne mase).
PHARMACOLOGICAL PROPERTIES
FARMAKOLOŠKE IMUNOLOŠKE LASTNOSTI
Anti-inflammatory and Antirheumatic products, Non-steroids, ATCvet code:
Farmakoterapevtska skupina: protivnetna in protirevmatična zdravila, nesteroidna (oksikami) Oznaka ATCvet:
Absorption Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 6.1 hours.
Absorpcija Meloksikam se po peroralnem dajanju povsem absorbira in doseže največje koncentracije v plazmi po približno 6, 1 ure.
Distribution There is a linear relationship between the dose of meloxicam administered and plasma concentration observed in the therapeutic dose range.
Porazdelitev Pri terapevtskem razponu odmerkov je med vnesenim odmerkom in koncentracijo v plazmi linearno razmerje.
The volume of distribution is 0.3 1/ kg.
Porazdelitveni volumen je 0, 3 l/ kg.
Metabolism Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound.
Presnavljanje Meloksikam se pretežno nahaja v plazmi in je tudi pomemben produkt pri biliarnem izločanju, medtem ko so v urinu samo sledi matične spojine.
Approximately 75% of the administered dose of meloxicam is eliminated via faeces and the remainder via urine.
Približno 75% vnesenega odmerka se izloči z blatom, preostanek pa z urinom.
microcrystalline cellulose xanthan gum carboxymethylcellulose sodium benzoate sodium saccharinate glycerol sorbitol citric acid monohydrate sodium hydroxide purified water
mikrokristalinska celuloza ksantan gumi karboksimetilceluloza natrijev benzoat natrijev saharinat glicerol sorbitol citronska kislina monohidrat natrijev hidroksid prečiščena voda
4/ 28 6.3 Shelf life
4/ 28 6. 3 Rok uporabnosti
Shelf life after first opening the immediate packaging:
2 leta Rok uporabnosti po prvem odpiranju neposredne ovojnine:
Turnhoutseweg 30 B-2340 Beerse, Belgium Tel: +32(0)14.60.21.11 Fax: +32(0)14.60.21.00
Turnhoutseweg 30 B- 2340 Beerse, Belgija Tel: +32( 0) 14. 60. 21. 11 Fax: +32( 0) 14. 60. 21. 00
Meloxivet 1.5 mg/ ml oral suspension for dogs
Meloxivet 1, 5 mg/ ml, peroralna suspenzija za pse
6/ 28 Special precautions to be taken by the person administering the veterinary medicinal product to animals
6/ 28 Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo
8/ 28 6.3 Shelf life
8/ 28 6. 3 Rok uporabnosti
10 ml presentation: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and clear polypropylene dosing syringe.
10 ml izvedba: rjava steklena steklenička (tip III) s polietilensko, za otroke varno zaporko, polietilenskim zamaškom in prozorno polipropilensko odmerno brizgalko.
30 ml and 150 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and clear polypropylene dosing syringe.
30 ml in 150 ml izvedba: rjava steklena steklenička (tip III) s polipropilensko, za otroke varno zaporko, polietilenskim zamaškom in prozorno polipropilensko odmerno brizgalko.
9/ 28 ANNEX II
9/ 28 DODATEK II
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
IZDELOVALEC( IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK( I) DOVOLJENJ( A) ZA IZDELAVO ZDRAVILA, ODGOVOREN( ODGOVORNI) ZA SPROŠČANJE SERIJE
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
IZDELOVALEC( IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN > IMETNIK( I) DOVOLJENJ( A) ZA IZDELAVO ZDRAVILA, ODGOVOREN( ODGOVORNI) ZA SPROŠČANJE SERIJE
Estrada Consiglieri Pedroso, 69 B Queluz de Baixo 2730-055 Barcarena Portugal
Estrada Consiglieri Pedroso, 69 B Queluz de Baixo 2730- 055 Barcarena Portugalska
11/ 28 ANNEX III
11/ 28 DODATEK III
13/ 28 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
13/ 28 PODATKI NA ZUNANJI OVOJNINI
Acute and chronic musculo-skeletal disorders.
Akutna in kronična mišično- skeletna obolenja.
Turnhoutseweg 30 B-2340 Beerse, Belgium
Turnhoutseweg 30 B- 2340 Beerse, Belgija
15/ 28 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
15/ 28 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Label bottle 10 and 30 ml
Z nalepko označiti stekleničko 10 in 30 ml
16/ 28 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
16/ 28 PODATKI NA ZUNANJI OVOJNINI
Carton box for bottle 10, 30 and 150 ml
Kartonska škatla za stekleničko 10, 30 in 150 ml
18/ 28 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
PRIMARNI OVOJNINI
Label bottle 150 ml
Z nalepko označiti stekleničko 150 ml
20/ 28 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
20/ 28 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Meloxivet 0.5 mg/ ml oral suspension for dogs
22/ 28 NAVODILO ZA UPORABO Meloxivet 0, 5 mg/ ml, peroralna suspenzija za pse
Janssen Pharmaceutica N. V.
Imetnik dovoljenja za promet z zdravilom Janssen Pharmaceutica N. V.
Lusomedicamenta S. A.
Izdelovalec, odgovoren za sproščanje serije Lusomedicamenta S. A.
- if your dog is pregnant or during lactation
- med brejostjo in laktacijo,
- if your dog is suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired
- če ima vaš pes gastrointestinalne motnje kot sta iritacija in krvavitev, oslabljeno delovanje jeter,
hepatic, cardiac or renal function and haemorrhagic disorders
srca ali ledvic ter hemoragične motnje,
- if your dog is hypersensitive (allergic) to the active substance or to any of the other ingredients.
- če je vaš pes preobčutljiv (alergičen) na zdravilno učinkovino ali katerokoli drugo sestavino,
- if your dogs is less than 6 weeks of age
- če je vaš pes mlajši od 6 tednov.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported.
Občasno so poročali o značilnih neželenih učinkih nesteroidnih protivnetnih zdravil, kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev) in apatija.
Dosage Initial treatment is a single dose of 0.2 mg meloxicam/ kg body weight on the first day.
Dosage Začetni odmerek prvi dan zdravljenja je 0, 2 mg meloksikama na kilogram telesne mase.
Route and method of administration
Route and method of administration
Shake bottle well.
Stekleničko
Push down and unscrew bottle top.
Stekleničko z Stekleničko
Attach the dosing syringe to the bottle by gently pushing the end onto the top the bottle
Stekleničko Stekleničko z Stekleničko
Turn the bottle syringe upside down.
Zaporko potisnite navzdol in jo odvijte.
Pull the plunger out until the black on the plunger corresponds to your dog’ s bodyweight in kilograms.
Na stekleničko pritrdite merilno brizgo, tako da jo nanjo previdno pritisnete.
Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle.
Brizgin bat toliko izvlecite, da se črna črta na njem ujema s telesno maso psa v kilogramih.
By pushing the plunger in empty the contents of the syringe onto the food.
obrnite z brizgo navzgor in brizgo z blagim zasukom snemite.
10.
24/ 28 10.
Do not use after the expiry date stated on the label and carton after EXP.
Ne uporabljajte po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Shelf life after first opening the container:
Rok uporabnosti po prvem odprtju vsebnika:
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zloženki.
10 ml presentation: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and an amber polypropylenedosing syringe.
10 ml: rjava steklena steklenička (tip III) s polietilensko, za otroke varno zaporko, polietilenskim zamaškom in rumeno rjavo polipropilensko odmerno brizgalko.
30 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and an amber polypropylene dosing syringe.
30 ml: rjava steklena steklenička (tip III) s polipropilensko, za otroke varno zaporko, polietilenskim zamaškom in rumeno rjavo polipropilensko odmerno brizgalko.
25/ 28 PACKAGE LEAFLET FOR:
25/ 28 Na trgu ni vseh velikosti pakiranj.
Meloxivet 1.5 mg/ ml oral suspension for dogs
NAVODILO ZA UPORABO Meloxivet 1, 5 mg/ ml, peroralna suspenzija za pse
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Če opazite kakršne koli resne stranske učinke ali druge učinke, ki niso omenjeni v teh navodilih za
10.
27/ 28 10.
30 ml and 150 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and clear polypropyle dosing syringe.
30 ml in 150 ml izvedba: rjava steklena steklenička (tip III) s polipropilensko, za otroke varno zaporko, polietilenskim zamaškom in prozorno polipropilensko odmerno brizgalko.
What is Metacam?
Kaj je zdravilo Metacam?
Metacam exists as an oral suspension (0.5 mg/ ml, 1.5 mg/ ml and 15 mg/ ml), a solution for injection (5 mg/ ml and 20 mg/ ml) and chewable tablets (1 mg and 2.5 mg).
Zdravilo Metacam obstaja v obliki peroralne suspenzije (0, 5 mg/ ml, 1, 5 mg/ ml in 15 mg/ ml), raztopine za injiciranje (5 mg/ ml in 20 mg/ ml) ter žvečljivih tablet (1 mg in 2, 5 mg).
What is Metacam used for?
Za kaj se zdravilo Metacam uporablja?
Metacam is used to relieve inflammation and pain in both acute and chronic musculo-skeletal disorders.
Zdravilo Metacam se uporablja za lajšanje vnetja in bolečin pri boleznih mišičja in okostja.
Metacam is used in cattle for acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs; use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle and as supportive therapy in the treatment of acute mastitis, in combination with antibiotics.
Zdravilo Metacam se uporablja pri govedu za akutne okužbe dihal skupaj z ustreznim antibiotičnim zdravljenjem za zmanjšanje kliničnih znakov, pri driski v kombinaciji s peroralnimi rehidracijskim zdravljenjem za zmanjšanje kliničnih znakov pri teletih, starejših od enega tedna, in mladem govedu, ki se ne doji, ter kot podporno zdravljenje pri zdravljenju akutnega mastitisa v kombinaciji z antibiotiki.
In pigs indications are use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation and for supportive therapy in the treatment of septicaemia and toxaemia around farrowing (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Indikacije pri prašičih so uporaba pri neinfekcijskih lokomotoričnih motnjah za zmanjšanje simptomov šepavosti in vnetja ter za podporno zdravljenje pri zdravljenju septikemije in toksemije ob oprasitvi (sindrom mastitis- metritis- agalakcija) skupaj z ustreznim antibiotičnim zdravljenjem.
Metacam is used in horses and dogs for the relief of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
Zdravilo Metacam se uporablja pri konjih za lajšanje vnetja in bolečin pri akutnih in kroničnih boleznih mišičja in okostja.
In horses, Metacam is also used for the relief of pain associated with colic.
Pri konjih se zdravilo Metacam uporablja tudi za lajšanje bolečin, povezanih s kolikami.
In dogs Metacam is also used to reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Zdravilo Metacam se pri psih uporablja tudi za lajšanje pooperativne bolečine in vnetja po ortopedskih kirurških posegih in kirurških posegih na mehkih tkivih.
The indication in cats is reduction of post-operative pain after a spay operation and minor soft tissue surgery.
Indikacija pri mačkah je lajšanje pooperativne bolečine po operaciji odstranitve jajčnikov in manjših kirurških posegih na mehkih tkivih.